C
Céline Charrier
Researcher at University of Nantes
Publications - 62
Citations - 2212
Céline Charrier is an academic researcher from University of Nantes. The author has contributed to research in topics: Osteosarcoma & RANKL. The author has an hindex of 25, co-authored 58 publications receiving 1830 citations. Previous affiliations of Céline Charrier include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.
Marie-Astrid Boutet,Marie-Astrid Boutet,Géraldine Bart,Géraldine Bart,Maël Penhoat,Maël Penhoat,Jérôme Amiaud,Jérôme Amiaud,Bénédicte Brulin,Bénédicte Brulin,Céline Charrier,Céline Charrier,Franck Morel,J.-C. Lecron,M. Rolli‐Derkinderen,A. Bourreille,Solenne Vigne,Cem Gabay,Gaby Palmer,B. Le Goff,B. Le Goff,Frédéric Blanchard,Frédéric Blanchard +22 more
TL;DR: It is suggested that only a minor subgroup of patients with RA or CD had an elevated IL‐36 agonists/antagonists ratio, versus 93% of patientsWith psoriasis, and distinct expression profiles may help to explain why only subgroups of RA and CD patients have a potentially elevated IL-36 agonist/antagonist ratio.
Journal ArticleDOI
Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment
Aude I. Segaliny,Amel Mohamadi,Amel Mohamadi,Blandine Dizier,Blandine Dizier,Anna Lokajczyk,Anna Lokajczyk,Régis Brion,Régis Brion,Rachel Lanel,Rachel Lanel,Jérôme Amiaud,Jérôme Amiaud,Céline Charrier,Céline Charrier,Catherine Boisson-Vidal,Catherine Boisson-Vidal,Dominique Heymann,Dominique Heymann +18 more
TL;DR: It is demonstrated that IL‐34 is expressed by osteosarcoma cells, is regulated by TNF‐α, IL‐1β, and contributes to osteosARcoma growth by increasing the neo‐angiogenesis and the recruitment of M2 macrophages.
Journal ArticleDOI
Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3.
Laurence Duplomb,Laurence Duplomb,Marc Baud'huin,Marc Baud'huin,Céline Charrier,Céline Charrier,Martine Berreur,Martine Berreur,Valérie Trichet,Valérie Trichet,Frédéric Blanchard,Frédéric Blanchard,Dominique Heymann,Dominique Heymann +13 more
TL;DR: It is shown for the first time that IL-6 inhibits RANKL-induced osteoclastogenesis by diverting cells into the macrophage lineage, and the functional role of activated-STAT3 and its form of phosphorylation in the control of osteoclineogenesis is demonstrated.
Journal ArticleDOI
Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis.
Marc Baud'huin,Marc Baud'huin,Romain Renault,Romain Renault,Céline Charrier,Céline Charrier,Anne Riet,Anne Riet,Anne Moreau,Régis Brion,Régis Brion,François Gouin,François Gouin,Laurence Duplomb,Laurence Duplomb,Dominique Heymann,Dominique Heymann +16 more
TL;DR: The data reveal that IL‐34 can be entirely substituted for M‐CSF in RANKL‐induced osteoclastogenesis, thus identifying a new biological activity for this cytokine and a contribution to the pathogenesis of GCTs.
Journal ArticleDOI
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma
Dominique Heymann,Benjamin Ory,Frédéric Blanchard,M.-F. Heymann,P Coipeau,Céline Charrier,Séverine Couillaud,J P Thiery,François Gouin,Françoise Rédini +9 more
TL;DR: The combination of ZOL and IFO was more effective than each agent alone in preventing tumor recurrence, improving tissue repair, and increasing bone formation as revealed by the analysis of trabecular architecture.